Literature DB >> 8421951

Traumatic brain tissue acidosis: experimental and clinical studies.

A Marmarou1, R Holdaway, J D Ward, K Yoshida, S C Choi, J P Muizelaar, H F Young.   

Abstract

We have been focusing on potential metabolic derangement associated with severe head injury and a clinical trail directed toward treating brain tissue acidosis is currently underway. More specifically, we based this study on the hypothesis that following brain trauma brain tissue acidosis develops which may contribute to the prolongation of coma and neurologic deficit. Tromethamine (THAM), a safe and low toxicity agent which buffers in major part by causing a hypocapnic alkalosis, was selected for trial. Patients admitted with GCS < 8 were randomized into one of three arms: control: THAM plus hyperventilation; hyperventilation alone. Each regimen was maintained for 5 days post injury. Our analysis of 3 and 6 months Glasgow outcome score showed that prophylactic hyperventilation retards recovery, and the use of THAM overcomes the apparent deleterious effects of hyperventilation. One explanation is that the reduced ICP instability observed in THAM treated patients may account for this improvement. Is THAM effective in buffering traumatized brain tissue? What factors account for improvement in ICP stability? We addressed these questions in experimental studies utilizing MR spectroscopy to measure brain lactate production and tissue pH in fluid percussed anaesthetized cats. The protocol was designed to match our clinical trial, and brain injured animals were randomized into control, THAM, and hyperventilated groups. We observed that brain lactate production increased with trauma and remained above control at 8 hrs post injury. Lactate production in THAM treated animals was not elevated. Highest lactate production was associated with injured animals treated with sustained hyperventilation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8421951     DOI: 10.1007/978-3-7091-9266-5_23

Source DB:  PubMed          Journal:  Acta Neurochir Suppl (Wien)


  7 in total

Review 1.  The role of repulsive guidance molecules in the embryonic and adult vertebrate central nervous system.

Authors:  Bernhard K Mueller; Toshihide Yamashita; Gregor Schaffar; Reinhold Mueller
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-09-29       Impact factor: 6.237

2.  Extracellular brain pH with or without hypoxia is a marker of profound metabolic derangement and increased mortality after traumatic brain injury.

Authors:  Ivan Timofeev; Jurgens Nortje; Pippa G Al-Rawi; Peter J A Hutchinson; Arun K Gupta
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-12       Impact factor: 6.200

Review 3.  THAM for control of ICP.

Authors:  F A Zeiler; J Teitelbaum; L M Gillman; M West
Journal:  Neurocrit Care       Date:  2014-10       Impact factor: 3.210

4.  Optimum serum glucose levels for patients with severe traumatic brain injury.

Authors:  Donald W Marion
Journal:  F1000 Med Rep       Date:  2009-05-28

5.  Delayed changes in regional brain energy metabolism following cerebral concussion in rats.

Authors:  Marek Buczek; Jamie Alvarez; Jaffar Azhar; Yinong Zhou; W David Lust; Warren R Selman; Robert A Ratcheson
Journal:  Metab Brain Dis       Date:  2002-09       Impact factor: 3.584

6.  The voltage-gated proton channel Hv1 plays a detrimental role in contusion spinal cord injury via extracellular acidosis-mediated neuroinflammation.

Authors:  Yun Li; Rodney M Ritzel; Junyun He; Tuoxin Cao; Boris Sabirzhanov; Hui Li; Simon Liu; Long-Jun Wu; Junfang Wu
Journal:  Brain Behav Immun       Date:  2020-10-08       Impact factor: 7.217

7.  Proton extrusion during oxidative burst in microglia exacerbates pathological acidosis following traumatic brain injury.

Authors:  Rodney M Ritzel; Junyun He; Yun Li; Tuoxin Cao; Niaz Khan; Bosung Shim; Boris Sabirzhanov; Taryn Aubrecht; Bogdan A Stoica; Alan I Faden; Long-Jun Wu; Junfang Wu
Journal:  Glia       Date:  2020-10-22       Impact factor: 7.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.